Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Softening up for a stink bid?
View:
Post by fredgoodwinson on Oct 30, 2020 9:46am

Softening up for a stink bid?

The upshot of the ‘mistake’ at the start of Phase II is that Lumeda and others look set to establish the commercial potential of TLD-1433 in the biggest cancer killer of all before Theralase shareholders have even got to know whether it might or might not be a competitor in non muscle-invasive bladder cancer.

 

Add that to a sustained campaign to suppress the share price and we`re already seeing capitulation apathy from punch-drunk retail shareholders selling at 13 cents when their intuition tells them that it should be 13 dollars and talk from people who have been here for years of grateful acceptance of an offer of $2-$3 per share - valuing what may soon be shown to be the non-invasive destruction of deep cancers at less than a billion dollars.

 

 

 
Comment by Johnandrose22 on Oct 30, 2020 10:36am
Thank you for your typically candid and insightful post, especially your not so subtle inference regarding the “mistake” made in Phase 2 dosimetry. I continue to find it difficult to believe it was a mistake. OK...I said it...again. John
Comment by floatinketucky on Oct 30, 2020 10:51am
Seems to me the same template for Phase 1 would have been used with simple write in for the allowance of the 2nd treatment.  It's really a slap in the face for the company and shareholders.  What if Covid had not caused the delay??  Jeez....    The company has accepted the blame and given the hospitial immunity from neglagance. And really the company had no choice ...more  
Comment by Hankerchief on Oct 30, 2020 11:01am
Theralase is possibly bordering on a highly effective therapeutic option for cancer/infection that could benefit millions of people and it's like they are running in mud IMO.  WTH?  Get your act together and get on with it FFS.....IMO and again IMO as RR would say.
Comment by CAinPlap on Oct 30, 2020 3:09pm
Hachet or Hachey job? ;) To be fair, doubt trial "misstake" was her fault. It is Dr. K's loyalty we need to question given his involvement with much larger, deeper pocketed companies.
Comment by Eoganacht on Oct 30, 2020 4:32pm
It is not a question of loyalty. It's a question of integrity. I believe Dr. Kulkarni will go with the solution which is most beneficial for cancer patients. If he put patient's lives at risk to make a few extra dollars he would not be a doctor. Just another dirty moneygrubber.
Comment by enriquesuave on Oct 30, 2020 5:02pm
I totally agree there Eoganacht.  We don't know how or why this bladder volume error occurred, but it definitely set the protocol straight once and for all.  It will ensure that no Urologist ever makes that mistake again as we now know one cannot compromise on bladder volume regardless of green light  intensity.IMO
Comment by Longholder99 on Oct 30, 2020 5:42pm
Agree with Eoganacht.....Dr K and the rest at UHN are not concerned with the comings and goings at TLT or the ramblings of rank and file bashers on some bullboard they probably havent heard of nor care to. Their reputations as researchers and physicians im guessing means more to them than interim results on just one of the projects they are involved in. The slip up was likely just that and was ...more  
Comment by Researchbased on Oct 30, 2020 6:09pm
Another amateure comment from a representative of the armchair quarterbacks club! ... lolll  Another one into plot theories, another one "that knows how it works"! ... ;-) CainPlap thinks that Dr. Kulkarni should have devoted all its time to only one clinical trial!  Wow! Should Dr. Jewett also have done the same? And all these other MDs in all their different practices over ...more  
Comment by enriquesuave on Oct 30, 2020 11:30am
Yes it's hard to believe it was a mistake given the optimisation changes made in PH1 on patients 5 & 6 which led to the early completion of that trial with perfect results.  They had further optimized the hardware following that success and I believe had doubled the light intensity of the fibre optic device.  Maybe that led them to estimate that perhaps they could use average ...more  
Comment by fredgoodwinson on Oct 30, 2020 12:30pm
Much appreciated John. Finding it difficult to move on from that ‘mIstake’ myself. Not sure whether it’s that each member of our learned MSAB individually failed to notice that they’d neglected to specify the manner of dosing or that the Chief Clinical Investigator - lacking any such guidance - then failed to refer back to them to specifically obtain it or whether it’s that for the incorrect ...more  
Comment by fredgoodwinson on Oct 30, 2020 12:45pm
Seems that you may have an agenda here too Tom - or is just (yuk) 'Gadgie'? 
Comment by fredgoodwinson on Oct 30, 2020 12:49pm
Tom I may have nmisinterpreted your post (it`s not difficult!) - if you weren`t personally insulting me please accept apologies for the response.
Comment by menoalittle on Oct 30, 2020 8:56pm
>> I continue to find it difficult to believe it was a mistake. moi aussi
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250



USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse